<DOC>
	<DOC>NCT02108262</DOC>
	<brief_summary>This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI).</brief_summary>
	<brief_title>A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Men or women, at least 18 years of age, with evidence of myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI), in the last week. Ongoing hemodynamic instability Evidence of hepatobiliary disease Evidence of chronic kidney disease (CKD) (Stage III, IV, or V), defined as moderate or severe renal impairment or if subject is receiving dialysis Evidence of unstable renal function History of acute kidney injury after previous exposure to an intravenous contrast agent. Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its components Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>